2135639-94-8

2135639-94-8 structure

Name: ATM Inhibitor-1
Chemical Name: ATM Inhibitor-1
CAS Number: 2135639-94-8
Molecular Formula: C₂₇H₃₆N₆O₃
Molecular Weight: 492.61
Catalog: Signaling Pathways Cell Cycle/DNA Damage ATM/ATR
Create Date: 2019-03-03 10:08:00
Modify Date: 2024-01-11 12:35:29
ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0.73 μM). ATM Inhibitor-1 exhibits anti-tumor activity[1].

Name	ATM Inhibitor-1

Description	ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0.73 μM). ATM Inhibitor-1 exhibits anti-tumor activity[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> ATM/ATR Signaling Pathways >> PI3K/Akt/mTOR >> ATM/ATR
Target	ATM:0.7 nM (IC50) ATM:2.8 nM (IC50, Cellular assay) PI3Kδ:0.73 μM (IC50) PI3Kγ:3 μM (IC50) PI3Kα:3.8 μM (IC50) PI3Kβ:10.3 μM (IC50) DNAPK:2.8 μM (IC50) mTOR:21 μM (IC50)
In Vitro	ATM Inhibitor-1 (Compound 21) is a highly potent, selective and orally active ATM Inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0.73 μM)[1]. In cellular assays, ATM Inhibitor-1 exhibits IC50s of 2.8 nM, >30 μM and >19 μM for ATM, ATR/PI3Kα and PI3Kβ/mTOR, respectively[1].
In Vivo	ATM Inhibitor-1 (Compound 21; 50 mg/kg p.o. once daily for 3 days every week starting 24 h post-irinotecan dosing, 21 days) in combination with 50 mg/kg irinotecan significantly reduces tumor growth in SW620 mice model[1]. Animal Model: SW620 mice model[1] Dosage: 50 mg/kg Administration: P.O., once daily for 3 days every week starting 24 h post-irinotecan dosing, 21 days Result: Inhibited the growth of tumor combined with 50 mg/kg irinotecan in SW620 mice model.
References	[1]. Barlaam B, et al. Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors. CS Med Chem Lett. 2018 Jul 13;9(8):809-814.

Molecular Formula	C₂₇H₃₆N₆O₃
Molecular Weight	492.61

2135639-94-8	2495096-26-7
2081969-24-4	2234897-35-7
1338540-81-0	1150701-66-8
1290490-78-6	1338545-01-9
2632-13-5	1579232-30-6
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
2228131-77-7	6906-52-1
930439-75-1	2287282-95-3
1018584-77-4	1375289-11-4